464 results about "Human papillomavirus" patented technology

An in vitro method is provided for screening human female subjects to assess their risk of developing cervical carcinoma which comprises screening the subject for expression of mRNA transcripts from the E6 and optionally the L1 gene of human papillomavirus, wherein subjects positive for expression of L1 and/or E6 mRNA are scored as being at risk of developing cervical carcinoma. Kits for carrying out such methods are also provided.

The invention discloses an exfoliative cells preserving fluid which is prepared from a pH buffering agent, an osmotic pressure maintenance agent, preservatives, a fixing agent for maintaining cellular morphology, an anticoagulant, a mucus softener, an antimicrobial reagent, a cleaning agent, a humectant and red blood cell destroying components. The components in the preserving fluid are reasonable in proportioning, and the exfoliative cells can be preserved at a long time under normal temperature, wherein the longest time can reach 2 years; mucus can be sufficiently dissolved and the red cells can be partially destroyed; a film production effect is good, cellular distribution is very even, cellular morphology is perfect, cytoplasm and cell nucleus demarcation is distinct, gradation is clear, and cytoplasm and cell nucleus transparency is very good, and the exfoliative cells preserving fluid can be simultaneously used for the HPV-DNA (human papillomavirus-deoxyribonucleic acid), Chlamydia and immunohistochemical test; the special liquid base preserving fluid used for the cytologic examination of other parts can be provided, an imported product can be completely replaced, and the cellular constituent with diagnostic significance can be sufficiently preserved; and the exfoliative cells preserving fluid is low in configuration cost and easy to popularize.

The present invention provides systems for identifying anti-viral agents. In particular, the invention encompasses reagents and strategies for identifying agents that inhibit or disrupt key protein-protein interactions that are important in the life cycle of papillomaviruses. The invention allows identification, production, and/or use of agents that reduce or inhibit the replication of HPV by inhibiting (e.g., precluding, reversing, or disrupting) the formation of the E1-E2 protein-protein complex. The invention also provides specific inhibitory agents, pharmaceutical compositions, and methods of using these inhibitors and pharmaceutical compositions for inhibiting viral replication in vitro. Methods are also described for the treatment and prevention of HPV infections and HPV-related diseases in patients.

The present invention provides human involucrin (hINV) sequences having tissue specific and cell type specific promoter activity. The sequences provided herein direct expression to suprabasal cells of stratifying epithelia. The invention further provides methods for the production of transgenic animals which contain a hINV promoter sequence which directs the expression of human papillomavirus 16 oncogenes (or other oncogenes). These animals display cervical and epidermal hyperplasias as well as cancer of the trachea, esophagus, colon, epidermis, anus/rectum, lymph nodes, spleen and lung. The animals of the invention provide a useful model for screening potential anti-neoplastic compounds, carcinogens, and co-carcinogens for a number of cancers.

This invention relates to one polymer enzyme linkage reaction fluorescence test method to dialogue dangerous human body nipple shape virus and to isolate DNA sample HPV gene type to test one set of dangerous HPV infection from patient by the method, wherein, it belongs to life science and biological technique. This invention agent case comprises one fluorescence meter PCR technique as base of multi-layer polymer enzyme reaction composed of multiple HPV positive lead object, reaction lead object and fluorescence detector.

Synthetic DNA molecules encoding papillomavirus proteins are provided. The codons of the synthetic molecules are codons preferred by the projected host cell. The synthetic molecules may be used as a polynucleotide vaccine which provides effective immunoprophylaxis against papillomavirus infection through stimulation of neutralizing antibody and cell-mediated immunity.

A method for detection and/or identification of HPV present in a biological sample comprising amplification of HPV polynucleic acids and of hybridization of said amplified polynucleic acids to a number of probes whereby a short fragment of the L1 gene of HPV is amplified after which, the amplimers are contacted with probes that specifically hybridize to the said short fragment of the L1 gene of at least one HPV type and a diagnostic kit to perform said method and primers and probes used in the said method.

The invention provides materials and methods for detection and typing of HPV infection using PNA probes. More specifically, methods are provided for detecting high-risk types of HPV infection with minimal numbers of PNA probes or using PNA probes to selectively amplify only high-risk types of HPV. Novel primer sequences are also provided.

The present invention relates to a method and kit for quantitative and qualitative determination of human papillomavirus, HPV, in a sample. More precisely, for quantitative and qualitative determination of oncogenic HPV to predict the risk of HPV infection resulting in cervical carcinoma. The method and kit enable simultaneous measurement of several oncogenic HPV types.

Fusion polypeptides and aggregates of polypeptides comprising papillomavirus-derived antigens, and compositions thereof and their use e.g. with adjuvants for immunogenic and vaccine purposes in eliciting e.g. HPV-specific immune responses. The polypeptides can be purified to result in aggregates which when in solution or dispersion can pass through a sterilisation filter, and in amorphous aggregates. An example of such a polypeptide is a fusion protein of human papillomavirus proteins L2 and E7.

Disclosed are chimeric HPV L1 proteins and virus like particles comprising the same which are capable of generating high titer neutralizing antibody responses against at least two HPV types. The disclosed chimeric HPV L1 proteins and VLPs are useful as therapeutic and prophylactic reagents, as well as reagents for diagnosing papillomavirus infection.

Recombinant papillomavirus capsid proteins that are capable of self assembly into capsomer structures and viral capsids that comprise conformational antigenic epitopes are provided. The capsomer structures and viral capsids, consisting of the capsid proteins that are expression products of a bovine, monkey or human papillomavirus L1 conformational coding sequence proteins, can be prepared as vaccines to induce a high titer neutralizing antibody response in vertebrate animals. The self assembling capsid proteins can also be used as elements of diagnostic immunoassay procedures for papillomavirus infection.

The invention provides a human papillomavirus HPV DNA fragment, a mix primer for human papillomavirus HPV DNA detection and/ or parting and application thereof. The mixed primer can specifically amplify to obtain one or a plurality of DNA sequences from HPV6, HPV 11, HPV 16, HPV 18, HPV 26, HPV 31, HPV 33, HPV 35, HPV 39, HPV 40, HPV 42, HPV 43, HPV 44, HPV45, HPV 51, HPV 52, HPV 53, HPV 54, HPV 55, HPV 56, HPV 58, HPV 59, HPV 61, HPV 66, HPV 68, HPV 70, HPV 72, HPV 73, HPV 81, HPV 82 and HPV 83, can be used for the human papillomavirus HPV DNA detection and/ or parting and prepared into a PCR kit. The invention can detect common types of HPV at a time, greatly improve the HPV detection efficiency, overcome the defect of missed detection of latent infection by a serology and IHC detection method, realize early diagnosis of HPV diseases, and is suitable for clinical HPV gene detection and parting and guides prevention and cure of cervical carcinoma.

The invention relates to an HPV16L1 polynucleotide sequence, and an expression vector, a host cell and application of the HPV16L1 polynucleotide sequence. The HPV16L1 polynucleotide sequence comprises an amino acid sequence of recombinant human papillomavirus (HPV) L1 capsid protein, a synthetic nucleotide sequence coding the amino acid sequence, and a recombinant expression vector and a hansenula polymorpha expression host strain comprising the nucleotide sequence. The invention also relates to the application of HPV16L1 protein consisting of the amino acid sequence and derivatives of the HPV16L1 polynucleotide sequence in preparing vaccine. According to the invention, by transforming the nucleotide sequence of HPV16L1 wild type virogene, the recombinant HPV16L1 capsid protein in a hansenula polymorpha system is efficiently expressed, and the HPV16L1 capsid protein can be industrially produced by using the hansenula polymorpha expression system; and compared with the conventional other eukaryotic expression systems, the hansenula polymorpha expression system has the advantages of high yield, low cost and the like.

Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E7, E7_11-19. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.

The invention relates to a vaccine against human papillomavirus (HPV) as well as a preparation method and an application thereof. Specifically, the invention provides the encoding sequence of an optimized human papillomavirus capsid protein L1 (HPV L1) suitable for expression in Pichia pastoris, and a method for efficiently producing HPV L1. The optimized HPV L1 gene is very suitable for expression in Pichia pastoris, and has the characteristic of high expression level and high stability. According to the invention, HPV L1 proteins and self-assembled virus-like particles can be obtained in an efficient, simple and cheap way. The invention also provides a vaccine composition comprising HPV virus-like particles.